- 8/20/08 — SynapseGenetically bred “fat rats” given vigabatrin experience dramatic weight loss.
- 7/14/08 — KENS-TV, videoReport by KENS-TV of San Antonio, Texas, on Catalyst’s cocaine trial
- 3/3/08 — Newsweek (PDF version) Cover story: "What Addicts Need"
- 12/18/07 — Rodman & Renshaw, transcript (PDF)
Rodman & Renshaw rates Catalyst "Market Outperform."
- 12/07 — The Ones to Watch (PDF)
Thomson Scientific rates CPP-109. See page 7
- 07/16/07 — BioCentury
"Product Development: Down-sizing the High"
- 07/05/07 — TIME magazine
"How We Get Addicted"
- 02/16/07 — Long Island Newsday
"Dulling dopamine's kick"
- 01/14/07 — Miami Herald
"Catalyst focuses on drug to treat addicts"
- 04/21/05 — Senate Testimony
Nora D. Volkow, MD, Director of NIDA, discusses promise of CPP-109
- 12/10/04 — VentureWire Lifescience
"Catalyst Looks for $10M Series B as it Plans Clinical Trials"
- 02/15/04 — NIDA Notes
"The Long Road to Medication Development: Cocaine Treatment Moves to Clinical Trials"
Top
Mail to a colleague